Amazon.com (AMZN) Received An FDA Warning Over Unapproved STI Drug Listings

• On 15 October 2026, Amazon.com (NasdaqGS:AMZN) received an FDA warning letter over unapproved drug products for sexually transmitted infections.

• The FDA cited multiple marketplace listings that it says were marketed as treatments or cures without required drug approvals.

• Regulators warned that continued sale of these items could trigger product seizures or injunctions if Amazon does not correct the issues.

• The FDA warning over unapproved STI treatments is important, but should sit alongside everything else you know about Amazon. Take a look at 5 other big wins we have identified for Amazon.com.

Consider widening your watchlist to other companies linked to digital infrastructure and cloud demand via 55 AI infrastructure stocks.

Amazon.com runs a large global retail and subscription platform, and this FDA action connects directly to how it manages third party health related listings…